Alto Neuroscience (ANRO) Income from Continuing Operations (2023 - 2026)
Alto Neuroscience (ANRO) posted Income from Continuing Operations of 26122000.0 for Q1 2026, down 71.25% sequentially from 15254000.0 in Q4 2025, and down 64.82% YoY from 74248130.92 in Q1 2025.
Powered by 
Analysis
Alto Neuroscience (ANRO) Income from Continuing Operations (2023 - 2026) Analysis & Trends
Alto Neuroscience has reported Income from Continuing Operations for 4 years, with the latest figure at 26122000.0 in Q1 2026.
- Quarterly Income from Continuing Operations fell 64.82% year-over-year to 26122000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 2273794000.0 (down 3479.2% YoY) and the FY2025 annual result came in at 111903000.0, down 15.18% from the prior year.
- Income from Continuing Operations slipped to 26122000.0 in Q1 2026 per ANRO's latest filing, from 15254000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 7295000.0 in Q1 2023 and troughed at 1853419000.0 in Q3 2025.
- A 4-year average of 183613692.31 and a median of 15254000.0 in 2025 frame the typical range for Income from Continuing Operations.
- The widest YoY moves for Income from Continuing Operations: up 2.64% in 2025, down 10975.11% in 2025.
- Over 4 years, Income from Continuing Operations stood at 10925000.0 in 2023, then plunged by 36.03% to 14861000.0 in 2024, then retreated by 2.64% to 15254000.0 in 2025, then tumbled by 71.25% to 26122000.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 26122000.0, 15254000.0, and 1853419000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Alto Neuroscience | 1.52 Bn | 1.52 Bn | - | -27.51 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -27.51 Mn |
| Mar 31, 2026 | -26.12 Mn |
| Dec 31, 2025 | -16.07 Mn |
| Sep 30, 2025 | -14.07 Mn |
| Jun 30, 2025 | -17.65 Mn |
| Mar 31, 2025 | -14.45 Mn |
| Dec 31, 2024 | -15.20 Mn |
| Sep 30, 2024 | -16.74 Mn |
| Jun 30, 2024 | -16.03 Mn |
| Mar 31, 2024 | -13.17 Mn |
| Dec 31, 2023 | -11.38 Mn |
| Sep 30, 2023 | -9.37 Mn |
| Jun 30, 2023 | -8.79 Mn |
| Mar 31, 2023 | -7.30 Mn |